• lumiracoxib It has been known that LOX is the

  2024-02-06

  

  It has been known that 5-LOX is the rate-limiting enzyme for the products of LTs, and LTs actively participate in the activation of neutrophils [10]. In our study, we determined whether 5-LOX was upregulated in pancreatic tissues during ANP. Moreover, we investigated whether the inhibition of expres

• Signaling through Axl can lead

  2024-02-06

  

  Signaling through Axl can lead to activation of the PI3K/Akt and Ras/MAPK pathways which promote cellular phenotypes (e.g., transformation, migration) consistent with pro-survival and pro-metastatic effects., , Inhibition of Axl activity by a variety of approaches (including pharmacologic, dominant

• In addition to the data provided by

  2024-02-06

  

  In addition to the data provided by the Ki16425 treatment in the K/BxN arthritis model, new findings from the study of two new LPA receptor antagonists confirm the involvement of the LPA pathway in the pathogenesis of experimental arthritis. In the study by Miyabe et al., the authors reported the tr

• br Introduction The term antioxidant derives from the preven

  2024-02-05

  

  Introduction The term antioxidant derives from the prevention of the oxygen consumption. In the late of 19th centuries, antioxidants were generally used in industrial processes such as against to metal corrosion, vulcanization of rubber. Later on, the use of antioxidants to prevent the rancidity

• br Conclusion br Competing interests

  2024-02-05

  

  Conclusion Competing interests Funding The Bolger Prostate Cancer Research Fund (no grant number), the National Institute of General Medical Sciences of the National Institutes of Health (1-R01-GM58553, G. B. Bolger, principal investigator), and the National Cancer Institute of the NIH to t

• br Materials and methods br Results br Discussion Diabetic

  2024-02-05

  

  Materials and methods Results Discussion Diabetic kidney disease (DKD) is the most common cause of end-stage renal disease [15], [16]. The pathogenesis of DKD is not fully understood, and there is no effective treatment. Although previous studies suggested that early lesions of DKD are foun

• br Results br Discussion By using an unbiased

  2024-02-05

  

  Results Discussion By using an unbiased proteomic screen for xCT binding partners, followed by functional validation, we have made the surprising discovery that mTORC2 regulates amino SSR 69071 mg metabolism in tumor cells by phosphorylating serine 26 of the cystine-glutamate antiporter xCT o

• Pituitary adenylate cyclase activating polypeptide PACAP is

  2024-02-05

  

  Pituitary adenylate cyclase-activating polypeptide (PACAP) is a member of the secretin/growth hormone-releasing hormone (GHRH)/vasoactive intestinal peptide (VIP) family, with potent anti-inflammatory and potent cytoprotective properties [[6], [7], [8], [9], [10], [11], [12], [13]]. PACAP exists as

• ADA catalyzes the deamination of adenosine and deoxyadenosin

  2024-02-05

  

  ADA catalyzes the deamination of adenosine and deoxyadenosine into their respective inosine nucleoside (Cristalli et al., 2001). This conversion is an initial step in a series of reactions responsible for lymphocyte proliferation and differentiation. Moreover, ADA is considered an indicator of cellu

• The present in vitro pharmacological experiments revealed

  2024-02-04

  

  The present in vitro pharmacological experiments revealed that the cholinergic up-regulation of VEGF expression in neurons and astrocytes was mainly mediated by nicotinic AChR and muscarinic AChR, respectively. In addition, neuronal VEGF expression was elevated by endogenous ACh in a manner that was

• Many metalloenzyme inhibitors consist of

  2024-02-04

  

  Many metalloenzyme inhibitors consist of two chemical components: the MBG, the portion of the inhibitor designed to bind to the metal, and the scaffold, the portion of the inhibitor recognized by the amino hiv fusion inhibitors residues that form the substrate-binding site of the metalloenzyme. The

• br Author contributions br Competing interests

  2024-02-04

  

  Author contributions Competing interests Transparency document Acknowledgments This research was funded by a TOP ZonMW grant (40-00812-98-10054) to R.O.E., a DFG grant (KR4391/1-1) and IZKF Erlangen grant (J36) to A.K. and supported in part by Centro de Investigación Biomédica en Red de

• cetp inhibitors What can we learn about the anticancer thera

  2024-02-04

  

  What can we learn about the anticancer therapeutic efficacy of Aurora kinase inhibitors from our experience with the Bcr-Abl inhibitors and the long term clinical consequence of their use in treating leukemias? As discussed, all Aurora kinase inhibitors developed to date are ATP-competitive inhibito

• CGP 53353 Compound was docked into the active site of Aurora

  2024-02-04

  

  Compound was docked into the active site of Aurora B kinase using Tripos sybyl-X ver. 2.1.1. The crystal structure of human Aurora B kinase cocrystallized with its potent inhibitor VX-680 was used for the docking analysis (PDB ID: ). The most likely binding conformations were selected based on the

• br Acknowledgements M M M is the William

  2024-02-04

  

  Acknowledgements M.M.M. is the William Dow Lovett Professor of Neurology and is supported by grants from the Michael J. Fox Foundation for Parkinson's Research, the American Parkinson Disease Association, the New Jersey Health Foundation/Nicholson Foundation, and by the National Institutes of Hea

14427 records 169/962 page Previous Next First page 上5页 166167168169170 下5页 Last page